Literature DB >> 29024440

Endothelial Vascular Function in Hypertensive Patients After Renin-Angiotensin System Blockad.

Leon Adriana Souza-Barbosa1, S Lvia E Ferreira-Melo1, Samira Ubaid-Girioli1, Eduardo Arantes Nogueira1, Juan Carlos Yugar-Toledo1, Heitor Moreno1.   

Abstract

It is unclear whether single and combined pharmacologic inhibition of the renin-angiotensin-aldosterone system have similar effects on endothelial function and blood pressure (BP). The authors evaluated 63 hypertensive patients divided into 4 groups (hydrochlorothiazide 25 mg/d; irbesartan [IRBE] 150 mg/d; quinapril [QUIN] 20 mg/d; or IRBE 150 mg/d + QUIN 20 mg/d) and 25 healthy normotensive subjects (normal) followed for 12 weeks. Endothelium-dependent dysfunction measured as flow-mediated dilation at Weeks 0 and 12 were: normal, 11.5%±2.4% vs 13.5%±2.0%; hydrochlorothiazide, 7.3%±2.0% vs 12.8%±3.1%; QUIN, 7.2%±2.8% vs 13.2%±2.1%; IRBE, 7.1%±2.8% vs 13.0%±2.9%; and IRBE + QUIN, 7.5%±1.9% vs 12.8%±3.0%. Nitroglycerin-mediated responses were: normal, 26.0%±1.9% vs 24.0%±2.5%; hydrochlorothiazide, 17.0%±2.2% vs 18.3%±2.6%; QUIN, 17.8%±3.2% vs 23.4%±3.0%; IRBE, 16.8%±3.6% vs 24.7%±2.0%; and IRBE + QUIN, 17.3%±3.0% vs 25.1%±2.5%. Antihypertensive therapy restored BP to normal and improved the endothelium-dependent and -independent dysfunction after renin-angiotensin-aldosterone system blockade. In a further finding, the combined effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade was not superior to the action of either of these treatments separately.

Entities:  

Year:  2006        PMID: 29024440      PMCID: PMC8109450          DOI: 10.1111/j.1524-6175.2006.05663.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  51 in total

1.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

2.  Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition.

Authors:  Azra Mahmud; John Feely
Journal:  Am J Hypertens       Date:  2002-04       Impact factor: 2.689

Review 3.  Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists.

Authors:  D J Campbell
Journal:  Clin Exp Pharmacol Physiol Suppl       Date:  1996

Review 4.  [Hypertension and vascular diseases: molecular and cellular mechanisms].

Authors:  T F Lüscher
Journal:  Schweiz Med Wochenschr       Date:  1995-02-18

5.  Non-invasive measurement of human endothelium dependent arterial responses: accuracy and reproducibility.

Authors:  K E Sorensen; D S Celermajer; D J Spiegelhalter; D Georgakopoulos; J Robinson; O Thomas; J E Deanfield
Journal:  Br Heart J       Date:  1995-09

6.  Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis.

Authors:  D S Celermajer; K E Sorensen; V M Gooch; D J Spiegelhalter; O I Miller; I D Sullivan; J K Lloyd; J E Deanfield
Journal:  Lancet       Date:  1992-11-07       Impact factor: 79.321

7.  Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.

Authors:  Juliá Segura; Manuel Praga; Carlos Campo; José L Rodicio; Luis M Ruilope
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2003-03       Impact factor: 1.636

8.  Effect of selective angiotensin II receptor antagonism and angiotensin converting enzyme inhibition on the coronary vasculature in vivo. Intravascular two-dimensional and Doppler ultrasound studies.

Authors:  K Sudhir; J S MacGregor; M Gupta; S D Barbant; R Redberg; P G Yock; K Chatterjee
Journal:  Circulation       Date:  1993-03       Impact factor: 29.690

Review 9.  Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: similarities and differences.

Authors:  George S Stergiou; Irini I Skeva
Journal:  Curr Top Med Chem       Date:  2004       Impact factor: 3.295

Review 10.  Pharmacologic blockade of the renin-angiotensin system: vascular benefits beyond commonly understood pharmacologic actions.

Authors:  James P Tsikouris; Craig D Cox
Journal:  Pharmacotherapy       Date:  2003-09       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.